Li Haoran, MD, PhD
@lihaoran
Followers
408
Following
550
Media
38
Statuses
175
Medical oncologist @KUcancercenter. Previously @Huntsmancancer, @UofT & #SYSUCC
Kansas City, KS
Joined September 2010
Just in @JAMANetworkOpen 👉 In pt level data from two ph3 trials (n=2187) 👉statin use associated with ⬆️ OS in advanced #prostatecancer treated with apalutamide. Congrats @ziremozay and @Soum_Roy_RadOnc Free access👉 https://t.co/tCO0bidsBr
@PCFnews @urotoday @OncoAlert
6
41
79
Now pannel discussion @md_anusha @lihaoran Dr. Weijing Sun and Dr. Christine Bestivina @KUcancercenter #MedEd #MedTwitter @OncoAlert @USMIRCNEWS #سرطان_الدم #المايلوما
0
5
5
Wondering about AI in #prostatecancer ? 🤔 Check this poster ➡️Utilizing ChatGPT for Assessing Disease Volume in Patients @lihaoran
@ASCO #GU25
1
6
13
Take home: For those still using GC x 4 cycles as NAC, practice should change to add Durva to GC pre and 8 cycles post. For those using DDMVAC, similar results can be achieved while saving IO for adjuvant using a risk adapted approach based on pathologic stage.
2
9
27
Excited to share that our poster was awarded the best poster award in the policy and preventive strategies category! #ESMO24 @myESMO Grateful for terrific mentorship from @neerajaiims and team @umangtalking @maughanonc @NeliMUlrich @montypal @Huntsman_GU @urotoday @OncoAlert
Make sure to stop by poster #1580P at #ESMO24 @myESMO 👉In @flatironhealth : we report disparities in NGS testing based on race-ethnicity and socioeconomic status in > 60,000 pts w/ breast, prostate, lung, colorectal, and pancreatic cancers 👇 @neerajaiims @urotoday @OncoAlert
13
19
49
Full house for @tompowles1 ‘s presidential talk of the results of the ph3 NIAGARA trial w/ neo-adj durva + gem-cis followed by surgery + adj durva in pts w/ MIBC #bladdercancer 👇🏻 ⭐️ HR 0.68 for EFS (primary endpoint) & 0.75 for OS ⭐️ pCR 37.3% w/ Durva @urotoday @OncoAlert
0
14
22
Today I was thrilled to visit @KUcancercenter @KUHospital and meet their staff, trainees, and community members to learn about the important research and care they provide in Kansas. Many thanks to Sen. @JerryMoran for his continued leadership in support of #CancerResearch!
3
13
57
Just in @JAMANetworkOpen 👉 Unacceptablely low rates of NGS testing in metastatic #ProstateCancer #bladdercancer in real world pts (worse in Black & Hispanic pts)@flatironhealth👇Proud of our postdoc, Chadi @chadihc98 , Yeonjung @yeonjungjohci, George @ggebraelmd & team👇
2
33
79
Heartiest congratulations to @neerajaiims and @AdrianaMColetta for @huntsmancancer Collaborative Award for RO1 grant 👉 randomized trial of creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression
10
29
85
Proud of @MartinZarba for presenting this #IMDC study. More follow up and patients required but it does highlight the importance of VEGF inhibition in very favorable patients. They are the most sensitive. #hypothesisgenerating #ASCO24 @OncoAlert
The IMDC story continues with a new very favourable group (good risk with no visceral mets and 3yrs since surgery).All the pts did well but Ipi/nivo was least impressive. Modest numbers & patient selection confounding, but there are VEGF mono sensitive slow growing tumors #ASCO24
0
19
35
Cabozantinib with or without PD-1/L1 inhibitors for metastatic clear cell renal cell carcinoma - @drenriquegrande
@MDAndersonNews @JournalCancer @ggebraelmd @vinay_onc @lihaoran @nsayeghmd @umangtalking @neerajaiims @maughanonc
https://t.co/pFk5sYYCHY
#OncoDaily #Oncology
0
5
29
Just in @EurUrolOncol: We present gene expression in denovo vs relapsed (metachronous) mHSPC #ProstateCancer 👉⬆️ inflammatory pathways in denovo vs. ⬆️ AR pathways in relapsed mHSPC Thanks to mentors @umangtalking @neerajaiims @Huntsman_GU @OncoAlert Link https://t.co/QD9BgfIQA9
2
24
66
#AUA24 @AmerUrological 👉 Most pts (63%) diagnosed with mCRPC (even in 2023) never received prior NHT. NHT remains most common Rx in 1L mCRPC (even in pts treated with prior NHT). @neerajaiims @PBarataMD @OncoAlert @urotoday @PCF_Science @Huntsman_GU
1
21
36
Just in @JAMANetworkOpen 👉Our paper on treatment trends and attrition rates for advanced #bladdercancer in the US👉2/3rd of patients did not receive even 2nd-line Rx. Grateful for mentorship by @umangtalking @neerajaiims. Link👉 https://t.co/V3e8GMcl8A @Huntsman_GU @OncoAlert
5
24
61
Just in @Cancer_Cell 👉Validation of the molecular clusters of the IMmotion151 trial in the JAVELIN Renal 101 dataset #kidneycancer: Excellent commentary highlighting these biomarkers by our fellow @chadihc98 👇 https://t.co/6FT646QLW5
@Huntsman_GU @OncoAlert @urotoday @kidneycan
1
41
87
#PancreaticCancer #ClinicalTrials are necessary to determine whether new treatments are beneficial to people living with the disease. Learn about a multicenter, phase 2 trial looking at a new drug combination: https://t.co/T2QCApmHPN or email ctnursenav@kumc.edu.
0
2
4
Just in @EurUrolFocus 👉🏻Pts w/ synchronous (Dx-Mx ≤ 3 mos) vs metachronous mRCC #kidneycancer treated w/ 1st line ICI Rx ➡️worse clinical outcomes 👇🏻 https://t.co/vW7BqPgLNH
@ggebraelmd @LuisMezaco @montypal @neerajaiims @Huntsman_GU @CityofHope_GU @urotoday @OncoAlert
0
22
44
Neoadjuvant chemo (NAC) has benefit in OPTICAL and FOxTROT! 👏🏽to all authors! A 🧵 https://t.co/FYgOGQG9CI
@JenSeligmann
ascopubs.org
PURPOSEThe role of neoadjuvant chemotherapy (NAC) in colon cancer remains unclear. This trial investigated whether 3 months of modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...
4
11
46
Just in @JournalCancer 👉Pts w/ clear cell mRCC #kidneycancer from real world Flatiron database s/p ICI Rx👉 Similar survival w/ cabo + ICI vs. cabo monoRx aligning w/ #CONTACT03 trial results @urotoday @OncoAlert @huntsmangu @umangtalking @neerajaiims 👇 https://t.co/NzsTan9ZF9
8
36
90